Cetuximab, an EGFR antibody, has been approved by the FDA for the treatment of colon cancer with wild-type KRAS, but not those with a KRAS mutation [23], and for the treatment of certain stages of head and neck cancer. Here, EGFR is linked to malignant colon neoplasm.